REDWOOD CITY, Calif.
Jan. 28, 2014
/PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced that the company will host a conference call and webcast on
Tuesday, February 4
4:30 p.m. Eastern Time
to discuss its fourth quarter and year-end 2013 financial results. The call and webcast will follow the release of the fourth quarter financial results after market close.
Conference Call Details
To access the live conference call on
4:30 p.m. Eastern Time
via phone, please dial (877) 303-7208 from
the United States
or +1(224) 357-2389 internationally. Please dial in approximately ten minutes prior to the start of the call.
To access the live and subsequently archived webcast of the conference call, go to the
section of the company's website at
. Please connect to the website at least 15 minutes prior to the call to allow for any software download that may be necessary.
About Genomic Health
, Inc. (NASDAQ: GHDX) is the world's leading provider of genomic-based diagnostic tests that address both the overtreatment and optimal treatment of early stage cancer, one of the greatest issues in healthcare today. The company is applying its world-class scientific and commercial expertise and infrastructure to lead the translation of massive amounts of genomic data into clinically-actionable results for treatment planning throughout the cancer patient's journey, from screening and surveillance, through diagnosis, treatment selection and monitoring. Genomic Health's lead product, the
Oncotype DX® breast cancer test
, has been shown to predict the likelihood of chemotherapy benefit as well as recurrence in invasive
and has been shown to predict the likelihood of recurrence in
ductal carcinoma in situ (DCIS)
. In addition to this widely adopted test,
Oncotype DX colon cancer test
, the first multi-gene expression test developed for the assessment of risk of recurrence in patients with
stage II and stage III
disease, and the Oncotype DX
prostate cancer test
, which predicts disease aggressiveness in men with low risk disease. As of
September 30, 2013
, more than 19,000 physicians in over 70 countries had ordered nearly 400,000 Oncotype DX tests. The company is based in
with European headquarters in
. For more information, please visit,
and follow the company on Twitter:
. To learn more about
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the attributes and focus of the company's product pipeline; the applicability of clinical study results to actual outcomes; the ability of any potential tests the company may develop to optimize cancer treatment and the potential economic benefits associated with the company's tests; the ability of the company to develop additional tests in the future; the size of markets and demand for the company's tests; and the company's ability to commercialize new tests and expand into new markets domestically and internationally. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially, and reported results should not be considered as an indication of future performance. These risks and uncertainties include, but are not limited to: the risks and uncertainties associated with the regulation of the company's tests; the results of clinical studies; the applicability of clinical study results to actual outcomes; our ability to develop and commercialize new tests; the risk that the company may not obtain or maintain sufficient levels of reimbursement, domestically or abroad, for its existing tests and any future tests it may develop; the risks of competition; unanticipated costs or delays in research and development efforts and our ability to obtain capital when needed and the other risks set forth in the company's filings with the Securities and Exchange Commission, including the risks set forth in the company's Quarterly Report on Form 10-Q for the period ended September 30, 2013. These forward-looking statements speak only as of the date hereof. Genomic Health disclaims any obligation to update these forward-looking statements.
NOTE: The Genomic Health logo, Oncotype, Oncotype DX, Recurrence Score, and DCIS Score are trademarks or registered trademarks of Genomic Health, Inc. All other trademarks and service marks are the property of their respective owners.
SOURCE Genomic Health, Inc.